Absence of GPR182 also determined increased intratumoral concentration of different chemokines (CCL2, CCL22, CXCL1, CXCL9 and CXCL10) (116), which was suggested to contribute to an increased recruitment of tumor infiltrating lymphocytes and, therefore, hypothesized as potential target for improved immunotherapy (116). The gene discussed is ACKR5; the disease is neoplasm.